

Supplemental Digital Content. The Supplemental Digital Content was not copyedited by *Archives of Pathology & Laboratory Medicine*.

Supplemental table 1. Intravesical therapy data following diagnostic transurethral resection of the tumor.

Therapy ^a	LG n=49/52	HG n=30/34	BORD-NUP n=18/21	BORD-MIT n=14/14	BORD-MIX n=16/17
Chemotherapy^b					
Mitomycin	15 (31%)	9 (30%)	7 (39%)	3 (21%)	7 ^c (44%)
Adriamycin	2 (4%)	3 (10%)	0 (0%)	1 (7%)	1 (6%)
Immunotherapy					
BCG ^d	4 (8%)	9 (30%)	3 (17%)	2 (14%)	1 (6%)
Interferon ^e	0 (0%)	1 (3%)	0 (0%)	0 (0%)	1 (6%)

^a Treatment data were available in 127/138 (92%) patients.

^b Single instillation on day of transurethral resection (except for one patient).

^c One patient received mitomycin for 2 months for 8 doses in total.

^d Six doses that comprise the induction phase over a period of 6 weeks (1 dose per week).

^e In addition to BCG.

Abbreviations: LG, Low grade papillary urothelial carcinoma; HG, High grade papillary urothelial carcinoma; BORD-NUP, borderline for nuclear pleomorphism ; BORD-MIT, borderline for mitoses, mitotic count $\geq 5/10$ high-power field; BORD-MIX, mixture of distinct LG and HG with HG component representing <50%.